denoemagene deradenovec — Full data
Q4 2026
We expect to present one-year Cohort 2 data and two-year Cohort 1 data from MyPEAK-1 in the fourth quarter of 2026.Source filing
TNYA biotech catalysts & pipeline
TENAYA THERAPEUTICS INC · Data as of 2026-09-08
Upcoming catalysts
denoemagene deradenovec — FDA meeting
Q4 2026
We are also engaging with regulatory authorities to obtain feedback on pivotal trial plans for TN-201 and plan to provide an update on progress in the fourth quarter of 2026.Source filing
denoemagene deradenovec — Regulatory decision
Q4 2026
The company plans to provide an update on the status of these discussions in the fourth quarter of 2026.Source filing
TN-401 — Interim data
Q4 2026
Tenaya expects to report additional interim data from the RIDGE-1 clinical trial in the fourth quarter of 2026.Source filing
TN-401 — FDA meeting
Q4 2026
We are also engaging with regulators on late-stage pivotal trial planning for TN-401 and plan to provide an update on the status of our discussions in the fourth quarter of 2026.Source filing
TN-401 — Regulatory decision
Q4 2026
Tenaya is currently engaging with regulators on late-stage pivotal trial planning for TN-401 and plans to provide an update on the status of its discussions in the fourth quarter of 2026.Source filing